Bristol-Myers Squibb: Hold Rating Amidst Mixed Market Performance and Revenue Projections

In a report released on June 13, Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a price target of $53.00.

Evan Seigerman has given his Hold rating due to a combination of factors related to Bristol-Myers Squibb’s current market performance and future projections. The ongoing launch of Cobenfy in the schizophrenia market is being closely monitored, with recent data showing a 16.2% week-over-week increase in total prescriptions. However, despite this growth, the current prescription trends suggest that the revenue for the second quarter of 2025 is expected to fall short of the Visible Alpha consensus estimate, with projections at $31.0 million compared to the consensus of $32.5 million.
Furthermore, Seigerman’s analysis indicates that while the company’s immuno-oncology and hematology segments are generating stable cash flows, the growth of new product launches is proceeding at a slower pace than anticipated. Additional considerations, such as potential inventory build and adjustments in gross-to-net discounts, introduce further variability to revenue estimates. These factors collectively support the view that the stock is fairly valued at present, justifying the Hold rating.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMY in relation to earlier this year.